Anthony D. Piscopio, Ph.D.

President & CEO

Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation.

Prior to this, Dr. Piscopio co-founded Array BioPharma (ARRY;NASDAQ) where he served as V.P. of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale and oncology drug discovery. Prior to founding Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division, Boulder, CO, and served as a research scientist at Pfizer. Dr. Piscopio was an NIH Postdoctoral Fellow at The Scripps Research Institute and received his Ph.D. at the University of Wisconsin-Madison.

 

Xuedong Liu, Ph.D.

Chief Science Officer

Xuedong Liu is a Professor of Chemistry and Biochemistry at the University of Colorado-Boulder. He received his Ph.D. in Genetics from the University of Wisconsin-Madison in 1994 with Professor Janet Mertz at McArdle Laboratory for Cancer Research. From 1995 to 2000, he was an NIH and DOD postdoctoral fellow at the Whitehead Institute for Biomedical Research with Professor Harvey F. Lodish at Massachusetts Institute of Technology. He has been on faculty of the University of Colorado-Boulder since 2000.

Professor Liu’s research interests include the biochemistry and systems biology of cell signaling. He focuses on understanding signal transduction mechanism of growth factors and small molecule ligands in normal and cancer cells. His laboratory also works on deciphering molecular mechanisms of neurodegenerative disorders such as Parkinson’s disease. Professor Liu has authored or co-authored more than 75 research papers and patents and is the coeditor of a book entitled “Computational Modeling of Signaling Networks”. In addition, Professsor Liu is an OnKure co-founder and is responsible for the developing the profile-specific histone deacetylase inhibitor platform which forms the basis of OnKure’s technology. Professor Liu is the recipient of Inventor of the Year Award in 2013 from the University of Colorado.

S. Gail Eckhardt, M.D.

Chief Medical Officer

S. Gail Eckhardt, MD is Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center where she also holds the Stapp/Harlow Endowed Chair for Cancer Research.

After graduating from the University of Texas Medical Branch in Galveston, Dr. Eckhardt completed her internship and residency at the University of Virginia Medical Center. After a post-doctoral fellowship at the Scripps Research Foundation, she completed her training in medical oncology at the University of California at San Diego.

Following fellowship, Dr. Eckhardt joined the faculty of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas, where she held the position of Associate Director of Clinical Research. In 1999, Dr. Eckhardt joined the faculty of the University of Colorado School of Medicine to establish a Phase I program. In 2004 she became the Director of the Developmental Center.

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Developmental Therapeutics Study Section. She is also a member of two NCI Steering Committees: Gastrointestinal and Investigational Drugs. In addition, Dr. Eckhardt has been an Associate Editor of Clinical Cancer Research, the Journal of Clinical Oncology, and Investigational New Drugs. Therapeutics Program in the University of Colorado Cancer Center.

Dr. Eckhardt is the Principal Investigator on three NIH grants involving early clinical trials, mentoring, and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 70 manuscripts and serves on numerous advisory boards. Her area of interest is in the preclinical and clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.

John DeMattei, Ph.D.

COO & VP of Chemistry

Dr. DeMattei is a pharmaceutical development expert with experience in the development of small molecule and oligonucleotide therapeutics. During his pharmaceutical development career, Dr. DeMattei has provided leadership to pharmaceutical development teams that have contributed to more than 25 INDs, 3 approved NDAs, and 1 approved BLA. Prior to joining OnKure, Dr. DeMattei served as the Sr. Director of Oligonucleotide Technology at Dynavax Inc. Dr. DeMattei received his academic training in chemistry at the University of Illinois, UCLA, and Harvard; and he has contributed to more than 30 issued patents and publications.

Joe Romano

President & CEO, ZZ Biotech, LLC.

Mr. Romano has worked with Michael and Selim Zilkha in the energy industry since 1989. Mr. Romano was Chief Executive Officer of Zilkha Biomass Energy, President and Chief Executive Officer of Zilkha Renewable Energy and Senior Vice President and Chief Financial Officer of Zilkha Energy Company. He presently serves as President and CEO of Olympic Energy Partners, chairman of the board of Contango Oil and Gas (NYSE: MCF), and director and Vice President of Laetitia Vineyard & Winery. He served as Chief Financial Officer, Treasurer, and Controller of Texas International Company from 1986 to 1988 and as its Treasurer and Controller from 1982 to 1985. Prior to 1982, Mr. Romano spent five years working in the Worldwide Energy Group of the First National Bank of Chicago. He earned a BA in economics and political science from the University of Wisconsin in Eau Claire and an MBA from the University of Northern Illinois. Mr. Romano serves on the Board of Managers of Socratech, ZZ Biotech’s parent company.

Donna Peak

Director

Donna Peak received her bachelor’s degree from the University of Colorado, Boulder and her Ph.D. in biology biochemistry from the University of Colorado, Boulder. Donna is a co-founder of OnKure and is engaged in several philanthropic endeavors including the establishment and oversight of the Kenneth R. Peak Brain and Pituitary Treatment Center at Methodist Hospital in Houston.

Guobao Zhao

Vice President

Guobao Zhou is a five-year veteran of the Venture Capital industry and is currently responsible for healthcare sector investing at Delian Capital. Before joining Delian Capital, Mr. Zhao served as R&D Manager at Entremed (NASDAQ: ENMD) and was responsible for business development activities. Prior to Entremed, Mr. Zhao served as a Research Scientist at PPD. Mr. Zhao’s current portfolio investments include, but are not limited to: MicuRx, Changxi, Uniceutiq and OnKure. Mr. Zhao received his BS degree in Pharmacy from Huazhong University of Science and Technology, and his MS (in AMMI) and MBA degrees from China Agricultural University.

Anthony D. Piscopio, Ph.D.

Scientific Advisor

Tony Piscopio is an OnKure co-founder and has served as Chief Executive Officer and a member of the OnKure Board of Directors since its founding in April, 2011. Dr. Piscopio is a serial entrepreneur with executive leadership experience spanning a 23 year career in the life sciences industry. Most recently, he served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation.

Prior to this, Dr. Piscopio co-founded Array BioPharma (ARRY;NASDAQ) where he served as V.P. of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale and oncology drug discovery. Prior to founding Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division, Boulder, CO, and served as a research scientist at Pfizer. Dr. Piscopio was an NIH Postdoctoral Fellow at The Scripps Research Institute and received his Ph.D. at the University of Wisconsin-Madison.

 

Xuedong Liu, Ph.D.

Scientific Advisor

Xuedong Liu is a Professor of Chemistry and Biochemistry at the University of Colorado-Boulder. He received his Ph.D. in Genetics from the University of Wisconsin-Madison in 1994 with Professor Janet Mertz at McArdle Laboratory for Cancer Research. From 1995 to 2000, he was an NIH and DOD postdoctoral fellow at the Whitehead Institute for Biomedical Research with Professor Harvey F. Lodish at Massachusetts Institute of Technology. He has been on faculty of the University of Colorado-Boulder since 2000.

Professor Liu’s research interests include the biochemistry and systems biology of cell signaling. He focuses on understanding signal transduction mechanism of growth factors and small molecule ligands in normal and cancer cells. His laboratory also works on deciphering molecular mechanisms of neurodegenerative disorders such as Parkinson’s disease. Professor Liu has authored or co-authored more than 75 research papers and patents and is the coeditor of a book entitled “Computational Modeling of Signaling Networks”. In addition, Professsor Liu is an OnKure co-founder and is responsible for the developing the profile-specific histone deacetylase inhibitor platform which forms the basis of OnKure’s technology. Professor Liu is the recipient of Inventor of the Year Award in 2013 from the University of Colorado.

Kevin Koch, Ph.D.

Scientific Advisor

Dr. Kevin Koch, Ph.D. has served as the President and Chief Executive Officer of Edgewise Therapeutics since July 2017 and a Venture Partner at OrbiMed Advisors, LLC since May 2016. Dr. Koch has been active in the life science industry for 25+ years with a focus on drug discovery, translational medicine and clinical development. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to joining Biogen, Dr. Koch was a Co-Founder of Array Biopharma Inc. and served as its President, Chief Scientific Officer and Director from May 1998 to November 2013. While there, he built a fully integrated R&D team that oversaw the invention of over 20 clinical development candidates in the multiple therapeutic areas. Prior to Array, Dr. Koch held senior positions at Amgen Inc. and Pfizer Central Research. Prior to in Array, Dr. Koch served as an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to April 1998 for Amgen Inc. From September 1988 to May 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator, Senior Research Scientist, and Project Coordinator for the Cellular Migration and Immunology Project Teams. Prior to acting as a consultant, Dr. Koch served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, Inc. from December 2013 to September 2015, where he managed global drug discovery and biomarker development as well as the immunology and hematology teams. Dr. Koch is the Treasurer and Board Member of the Inflammation Research Association. Dr. Koch has been a Director of miRagen Therapeutics, Inc. since February 2017. Prior to joining miRagen Therapeutics Board, he served as a Member of Private Miragen’s Board of Directors since July 2016. He is a Founding Board Member of Skyhawk Therapeutics, Inc. Dr. Koch serves on the boards of Neurogastrx, Inc. and Encycle Therapeutics and consults with several life science companies. Dr. Koch served as a Director of Array Biopharma, Inc. from May 1998 to October 24, 2012. He is a Director of Skyhawk Therapeutics, Inc. He is a co-author or inventor of multiple patents and publications. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York in 1983, Stony Brook and his Ph.D. in Synthetic Organic Chemistry from University of Rochester in 1988 and M.S in organic chemistry from University of Rochester in 1986.

Lia Gore, M.D.

Scientific Advisor

Dr. Gore joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2001. She trained in Pediatrics at Children’s National Medical Center and the University of Colorado. She completed her fellowship training in pediatric hematology/oncology/bone marrow transplantation at the University of Colorado Cancer Center and Children’s Hospital Colorado.

Dr. Gore is a member of the Developmental Therapeutics (phase I clinical trials) Program, where she also directs the Early Phase Hematological Malignancies Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. She is the founder and the Program Leader of the Experimental Therapeutics Program at Children’s Hospital Colorado.

She co-founded and co-directs the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) and collaborates regularly with European Investigators on international phase I oncology studies. Dr. Gore’s primary interests are in leukemias and sarcomas. She has received funding from the National Cancer Institute, the Leukemia and Lymphoma Society, Alex’s Lemonade Stand, and numerous foundation awards. She has more than 65 publications of her work and has lectured extensively nationally and internationally.

Pamela Munster, M.D.

Scientific Advisor

Dr. Munster’s clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. Pam has been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, her main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer.  Her basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, Dr. Munster has shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.